文献速递免疫规划传染病防控与疫情报告

BNT162b2新冠疫苗接种前后口咽部疱疹病毒排毒情况

Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.
PubMed 文献 · Vaccine · 2021-08-30

本研究对免疫正常的成人接种BNT162b2疫苗前后进行口咽部疱疹病毒1-7型多重PCR检测,共103对样本。结果显示接种后一周各型疱疹病毒及任何疱疹病毒的检出率与接种前相比均无显著差异。未发现BNT162b2接种后口咽部疱疹病毒再激活增加的证据。

要点

  • 接种BNT162b2后一周口咽部疱疹病毒排毒率与接种前相似。
  • 各型疱疹病毒(HSV1、EBV、HHV6、HHV7等)接种前后检出率无显著变化。
  • 研究不支持BNT162b2接种增加口咽部疱疹病毒再激活的假设。

核心结论

  • 未发现BNT162b2接种后一周口咽部疱疹病毒再激活增加的证据。

研究设计与样本

  • 免疫正常成人接种BNT162b2前及接种后一周配对采集口咽样本,用多重PCR检测疱疹病毒1-7型,共103对样本。

主要发现

  • HSV1检出率接种前3.9% vs 接种后5.8%(p=0.75);EBV 14.6% vs 17.5%(p=0.63);HHV6 4.9% vs 7.8%(p=0.55);HHV7 71.8% vs 72.8%(p=1);任何疱疹病毒73.8% vs 74.8%(p=1)。
  • HSV2、VZV、CMV接种前后检出率均为0%或接近0%,无统计学比较。

临床怎么用

  • 对于免疫正常成人,BNT162b2接种后一周口咽部疱疹病毒再激活风险未见增加,可据此缓解相关顾虑。

局限性

  • 样本仅限免疫正常成人,排除了使用局部类固醇或有症状疱疹病毒感染者。
  • 仅观察接种后一周的口咽部排毒,未评估其他部位或更长时间窗口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Concerns were raised over an increase in Bell's palsy, herpes simplex and herpes zoster after BNT162b2 vaccination, all are manifestations of herpesviruses reactivation. As herpesviruses commonly reactivate in the oropharynx, we have hypothesized that oropharyngeal shedding of herpesviruses will increase after vaccination. METHODS: Immune-competent Adults, excluding those using topical steroids or manifesting symptomatic herpesvirus infection, were sampled before BNT162b2 vaccination and one week after. Herpesviruses 1-7 shedding was tested with a multiplexed PCR. RESULTS: In 103 paired samples the prevalence of herpesviruses was similar before and after vaccination: HSV1, 3.9% vs. 5.8% (p = 0.75); HSV2, 0% vs. 1% (p = not applicable, NA); VZV, 0% vs. 0% (p = NA); EBV, 14.6% vs. 17.5% (p = 0.63); CMV, 0% vs. 0% (p = NA); HHV6, 4.9% vs. 7.8% (p = 0.55); HHV7, 71.8% vs. 72.8% (p = 1); any herpesvirus, 73.8% vs. 74.8% (p = 1). DISCUSSION: We did not find evidence for increased oropharyngeal reactivation of herpesviruses one week after BNT162b2.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Brosh-Nissimov T, Sorek N, Yeshayahu M, et al. Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19. Vaccine. 2021. PMID: 34481701. doi:10.1016/j.vaccine.2021.08.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。